Enzalutamide significantly improves overall survival (OS) of patients with metastatic hormone- sensitive prostate cancer (mHSPC). However, ∼10% of patients will die within 2 years. PCPro is a plasma l...

This cohort study evaluates the time necessary to accurately document a persistent prostate-specific antigen level after radical prostatectomy.

Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) radioligands has an established role in the assessment of recurrence…

Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.

This nonrandomized clinical trial evaluates physician-reported late toxic effects and 2-year patient-reported outcomes following post–radical prostatectomy stereotactic body radiotherapy.

We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised…

To our knowledge, this is the first randomised trial for metachronous PET-detected nodal recurrences comparing two local treatment approaches (MDT and ENRT) in combination with 6 months of androgen de...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO G...

Abstract. Early cancer diagnosis is crucial but challenging owing to the lack of reliable biomarkers that can be measured using routine clinical methods. The identification of biomarkers for early det...

177Lu-rhPSMA-10.1 is a novel radiohybrid prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy for prostate cancer. We conducted preclinical analyses on non–tumor-bearing BALB...

This Review provides an overview of the main targetable surface proteins in prostate cancer, defined as the surfaceome, discussing the mechanisms of action and efficacy of currently available drugs ta...

On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto).

This randomized, noninferiority trial of biopsy-naive men compares the detection of Gleason Grade Group ≥2 prostate cancer using microultrasonography-guided and MRI fusion-guided biopsy.

In this post-hoc analysis of a phase 3 randomized controlled trial comparing apalutamide versus placebo in metastatic castration-sensitive prostate cancer, patients with two or less bone metastases h...

Trials comparing moderately hypofractionated radiotherapy (MHFRT) to conventionally-fractionated radiotherapy (CFRT) for prostate cancer have varied c…

This cohort study evaluates the time necessary to accurately document a persistent prostate-specific antigen level after radical prostatectomy.

Prostate Cancer and Prostatic Diseases - Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A...

Selection of patients harboring mutations in homologous recombination repair (HRR) genes for treatment with a PARP inhibitor (PARPi) is challenging in…

YouTube video by OncoAlert 360

This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year active monitoring.